American Diabetes Association 86th Scientific Sessions 2026

The 2026 American Diabetes Association’s (ADA’s) Scientific Sessions is the largest and most prominent conference in the world focused on diabetes, bringing together research, clinical care, and innovation. The scientific program features over 200 sessions designed to expand professional knowledge and highlight the latest breakthroughs in diabetes care, including symposia, late-breaking clinical trials, and panel discussions. It distills the latest care standards from the ADA’s Standards of Care in Diabetes and convenes the professional community to share ideas and network.
Learning Objectives

Evaluate new pharmacological advancements and adjunct therapies, such as GLP-1 receptor agonists and dual agonists, for managing Type 1 and Type 2 diabetes.

Understand the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and automated insulin delivery systems into clinical health care delivery.

Apply a holistic approach to diabetes care that addresses the intersection of heart, kidney, and metabolic health.

Identify and implement novel strategies for hypoglycemia prevention, weight management, and tackling diabetes-related complications.

Translate updated nutritional guidelines, behavioral interventions, and ADA Standards of Care into practical patient management strategies across diverse populations.

Target Audience

Annually welcoming over 12,000 researchers and clinicians, including physicians, nurses, endocrinologists, cardiologists, registered dietitian nutritionists, and others, this conference distills the latest care standards from the ADA’s Standards of Care in Diabetes, brings the newest research to the forefront, and convenes the diabetes professional community to share ideas, network, and form connections.
Best for Endocrinologists, Cardiologists, Nephrologists, Primary Care Physicians, and Registered Dietitian Nutritionists.

Topics

GLP-1 Receptor Agonists: What’s New in 2026?

REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema

Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes—Phase 1 and 2 Results

From Pen to Pill: Achieving a Paradigm Shift in Type 2 Diabetes—The Orforglipron “ACHIEVE” Clinical Trial Program

AI and Innovation for Clinical Health Care Delivery in DM

Where Heart, Kidney, and Metabolism Collide: Innovations in the Holistic Approach to Care

The New Frontier of Hypoglycemia Prevention: Pathophysiology, Therapies, Technology, and Care

From Patients to Partners Elevating Voices in Diabetes and Obesity Care President Health Care Education Address and Distinguished Internatio

Illuminating Dexcom Innovations Across the Metabolic Continuum Stelo Supporting Health Behavior Change and Dexcom G7 15 Day with Smart Basal

MiniMed Introducing New Insulin Delivery Systems

National Scientific Health Care Achievement Awards Presentation Outstanding Scientific Achievement Award Lecture and Outstanding Educator in

2026 ADA State of Type 1 Diabetes

2026 DiabetesDiabetes CareDiabetologia Symposium Where Are the Islet Lesions Underlying Type 2 Diabetes

ADA Diabetes Care Symposium The Oscillation of Diabetes and the Environment

ADA Diabetes Journal Symposium Non-Classical Complications of DiabetesEpidemiology Mechanism Treatment

ADA Diabetes Obesity and Cardiometabolic CARE DOCM CARE Journal Symposium The Cost of Obesity and its Treatment

ADA DSMESNutrition Symposium Disordered Eating in Diabetes and Obesity

ADA ERP Symposium Standardizing Diabetes Education on a Global Level

ADA Statement on Diabetes Technology in Primary Care

Adapting Diabetes Care for All With Felicia Hill-Briggs Trailblazer in Health Equity Award Lecture

Addressing the Growing Diabetes Epidemic Global Perspectives

Advances in Metabolic Therapeutics A Focus on Insulin Sensitivity and Adipose Function

Advancing Diabetes Epidemiology with Real-World Data and AI

AI Integration into diabetes technology

Albuminuria and Cardiovascular Risk The Power of Early Screening Detection and CKD Diagnosis

Amylin as a Novel Diabetes and Obesity Therapy

Anticipated and Unanticipated Side Effects of SGLT2 Inhibitors in Diabetes

Are GLP-1 Receptor Agonists Safe for the Eyes

Are We Ready to Meet the Needs of Older Adults with Type 1 Diabetes

AZD5004 A Novel Oral Small Molecule GLP 1 Receptor Agonist OverweightObesity VISTA and Type 2 Diabetes SOLSTICE Phase 2 Trial Results

B Cells in Type 1 Diabetes Hidden Culprits or Passive Participants

Beta-Cell Replacement in Pediatric Type 1 Diabetes Promise and Perspective

Beyond A1C New Ways to Measure Disease Progression in Early-Stage Type 1 Diabetes With ADA Presidents Select Abstract Presentation

Beyond Conventional Care Regenerative Medicine and Smart Dressings for Diabetic Foot Ulcer

Beyond Engraftment Functional Readouts Counterregulation and the Lived Experience of Islet Transplantation

Beyond Glucose Monitoring The Next Revolution of Diabetes Sensing Technology with Libre

Beyond Insulin Adjunctive Therapies for Pediatric Type 1 Diabetes

Beyond Screening Supporting Mental and Behavioral Health among Youth and Families at Risk for Stage 3 Type 1 Diabetes

Beyond Sugar Synapses and Senescence

Biology and Assessment of Cardiovascular Risk

BMI on Trial Should It Still Define Obesity

Breaking the Pain Chain Practical Strategies for Diabetic Neuropathy from Diagnosis to Treatment

Bridging the Gap Advancing Stem CellDerived Beta-Cell Therapy toward Widespread Clinical Use

Bridging the Gap Real-Time Diabetes Technology Organizational Readiness and Policy Solutions to Advance Care

Building a Multidisciplinary Model for Behavior Change in Cardiometabolic Health

Central Command or Can We Insights into whether Modulating the Nervous System Can Improve Metabolic Health

Clinical Algorithm for the Identification Monitoring and Management of Elevated Ketones in Ambulatory Settings

Consensus or Controversy Hot Topics in Nutrition 2026

Contemporary and Emerging Diabetes Technologies and Therapies Psychosocial and Behavioral Considerations With Richard R Rubin Award Lecture

Continuous Ketone Monitoring for the Masses Risky or Rewarding

Control-IQ in Pregnancy Results from the CIRCUIT Randomized Controlled Trial

Controlling the Metabolic Phenotype of Fat New Insights into Local and Distal Signals

Counterregulatory Responses to Hypoglycemia New Tools and Therapeutic Levers

Decoding Islet Electrophysiology Channels Pumps and Metabolic Coupling

Determinants of B-Cell Immunogenicity and Survival in Type 1 Diabetes

Diabetes Care and Education for Everyone Wherever They Are

Diabetes on the Radar From Smart Data to Smarter Policy

Diabetes Prediction with Polygenic and Metabolic Risk Scores

Diabetes Technology Use Across Life Situations

Diabetes Year in Review Major Advances and Discoveries

Discussion on Behavioral Medicine and Psychology Beyond BoundariesExpanding Your Behavioral Medicine Research Portfolio

Discussion on Clinical Centers and Programs Diabetes Management in Older AdultsChallenges and Opportunities

Discussion on Diabetes and Cardiovascular Disease Implementing a Multi-Disciplinary Approach in Patients with Diabetes and Cardiovascular Di

Discussion on Diabetes in Primary Care Optimizing Use Safety and Tolerability of Diabetes Medications

Discussion on Diabetes in Youth From Uncertainty to ActionMobilizing Advocacy for Type 1 and Type 2 Diabetes Amid Shifting Landscapes

Discussion on Diabetes Self Management Education and Support DSMES Advancing Prandial Insulin Education Within DSMESFindings from a Toolkit

Discussion on Diabetes Technology Addressing Unmet Needs in Diabetes TechnologyExpanding Access to Devices

Discussion on Exercise Physiology MoTrPACWhat Does It Tell Us About Diabetes and Physical Activity

Discussion on Eye Health Use of AI in Diabetic Retinopathy Screening

Discussion on Foot Care Revolutionizing Diabetic Limb SalvageVascular Innovation Bone Health and Regenerative Strategies in Lower Extremitie

Discussion on Health Care Delivery and Quality Improvement From Best Practices to ValueScaling Diabetes Expertise Through Innovation

Discussion on Immunology and Beta-Cell Replacement Immune Tolerance in Type 1 DiabetesHarnessing the Power of Regulatory T Cells

Discussion on Islet Biology Development and Function Small but MightyExtra Islet Beta Cells are Preserved or Lost in Type 1 Diabetes

Discussion on Nutritional Science and Metabolism Diabetes and Nutrition Across the Perinatal ContinuumFrom Preconception to Postpartum

Discussion on Obesity Reclaiming the Full Spectrum of Obesity Care

Discussion on Pregnancy and Reproductive Health Adverse Outcomes in GDM-Hyperglycemia or Obesity

Discussion on Public Health and Epidemiology Leveraging Technology to Disseminate Diabetes Care to Under-Resourced Populations

Discussion on Womens Interprofessional Network of the ADA WIN ADA The Adaptive EdgeHow to Lead Through Change Panel Discussion

Diverse Nutritional Approaches to Modify Metabolism in Type 2 Diabetes

Early Pregnancy Diabetes Screening Reexamined GO MOMs or Hold Tight

Emerging Insights from Type 1 Diabetes Immunotherapy Clinical Trials

Empowering Populations Diabetes Self Management Education in Practice

Engaging Science Talks that Matter

Everyone Should Screen for PAD

Exercise in the Age of Digital Health

Exercise Signals and the Interorgan Metabolic Dialogue

Evolving Therapies for MASH

Exercise Breaks

Exercise Training Fatigue and Motivation

Expanding Health Access Translating Science into Practice Through Community-Engaged Approaches

Expanding the Beta-Cell Pool Whats New with Proliferation Neogenesis and Transdifferentiation

Explore Advancements in Type 1 Diabetes Management

Food Is Medicine Outcomes for Diabetes Management Comparative Effectiveness across Populations

From Evidence to the Plate What the New Nutrition Guidelines Mean for Diabetes Care

From Innovation to Integration Redefining the Scale and Sustainability of Diabetes Prevention Through a National Framework

From Plate to Pancreas Mechanisms Linking Diet to Diabetes With ADA Presidents Select Abstract Presentation

From Symptoms to Solutions The Patient Experience with Korlym mifepristone Treatment

Frontiers in Diabetic Nerve Health Biomarkers Risk Diagnosis and Treatment

Getting Along with Your Algorithm

Global Advances in Research to Address Heterogeneity of Diabetes NIDDK

Global Perspectives on Obesity Care

GLP-1 and What Else Preclinical Obesity Studies

GLP-1 Receptor Agonists The Optimal First-Line Therapy for Early Pediatric Type 2 Diabetes

GLP-1RA Across the Lifespan Who When and at What Cost

Glucagon Pharmacology as a Metabolic SignalA Lightning Talk Series

Glucagon Takes the Stage Regulation Secretion and When the Pancreas Goes Off-Script

Goals in Common Recent Updates to the GuidelinesBlood Pressure Lipids and Heart Failure

Harnessing Big Data to Decode Immune Mechanisms in Type 1 Diabetes

Harnessing Technology to Tackle Diabetes Distress Innovations across Diabetes Types and Life Stages

Hepatic Signaling Networks Driving Metabolic Dysfunction and MASLD

Hope or Hype Microbiome as New Frontier for Type 2 Diabetes and Obesity

How Do Lipoproteins Control Blood Glucose LevelsInsulin Secretion Insulin Sensitivity

How Do We Close Gaps in Access to Obesity Care

How Does MASLD Impact Lipoprotein Biology and Cardiovascular Risk with Obesity and Diabetes

How to Best Combine Therapies for Patients with Diabetic Kidney Disease

Human Islet Cell Identity and Organization

Human Studies in Obesity Treatment Emerging Therapeutic Options and Strategies for Decision-Making

Hypercortisolism The Evidence The Evolution The Implications

Hypoglycemia across Contexts Risk Recognition and Real-World Safety With ADA Presidents Select Abstract Presentation

Hypothalamic Circuits and Neuroendocrine Control of Glucose Homeostasis

Identification and Stratification of Patients at High CV Risk without a Prior MI or Stroke Insights from Real-World Evidence and the VESALIU

Immediate AI Integration into Health Care Delivery Considering Costs Quality and Clinician Burnout

Immune Heterogeneity and Endotypes in Type 1 Diabetes Insights from Human Studies and Humanized Models

Immune Modulatory Strategies for Next-Generation Cell Therapies

Immune System Engineering for Type 1 Diabetes From Mechanisms to Therapies

In Search of Novel Therapeutic Targets in Diabetic Retinopathy

Innovative Approaches to Weight Management

Inpatient Glucose Management Clinical and Quality Perspectives in the Age of eCQMs

Insulin Resistance A Cause or Consequence of Metabolic Dysfunction

Interorgan and Intercellular Cross Talk in Steatotic Liver

Is Obesity Accelerated Aging A Physiologic Perspective

Its Not Up for Debate Paracrine Signaling Is Critical in Shaping Insulin Secretion

Joint ADAAACC Symposium Expecting the BestLaboratory Issues in the Diagnosis and Management of Diabetes in Pregnancy

Joint ADAInternational Diabetes Federation IDF Symposium What Is Malnutrition-Related Diabetes

Joint ADAIPITA Symposium Engineering Transplantation Sites to Improve Beta-Cell Survival and Function

Joint ADAISPAD Symposium A Global Perspective on Pediatric Type 1 Diabetes Screening

Kelly West Award for Outstanding Achievement in Epidemiology Lecture

Lady Parts of Life with Diabetes Behavioral and Psychosocial Care for Women

Lancet Journal Symposium Cardiometabolic Multiple Long-Term Conditions MultimorbidityEpidemiology Mechanisms Models and Management

Lessons from Islet Biology for Next-Generation Therapies

Level 1 Hypoglycemia Does It Really Matter

Make New Friends but Keep the Old Updates on Insulin Therapy in Pregnancy

Management of Diabetic RetinopathyClinical Perspective

Managing Diabetes across the Cancer Continuum From Treatment to Survivorship

Mapping Diabetes Epidemiology in a Changing US Demographic Landscape

Maternal Metabolic Health In and Beyond Pregnancy

Maternal Metabolic Imprinting New Insights on Developmental Origins of Diabetes and Obesity

Mechanisms and Treatments for Autonomic Dysfunction Current Evidence and Emerging Directions

Metabolic and Glycemic Profiles in Pregnancies Affected by Diabetes

Metabolic Control in Obesity and Diabetes via Interoception

Metabolic Programming during Development and Aging

Mitochondrial Energetics in Obesity

Molecular and Therapeutic Strategies for Diabetes

Molecular Architecture of Diabetic Retinopathy Genes and Epigenomics

Molecular Transducers of Insulin Action and Insulin Resistance

Multiomic Approaches and Resources for Providing Insights into Diabetes Pathophysiology

Muscle Loss in GLP-1 Receptor AgonistInduced Weight Loss A Real Concern or Much Ado about Nothing

Neonatal and Childhood Outcomes of Dysglycemia in Pregnancy With Norbert Freinkel Award Lecture

Neuronal Circuits and Plasticity Linking Energy Balance and Feeding in Obesity

New Directions and Novel ApproachesEarly Stage and PilotFeasibility Research on Innovations in Diabetes Behavioral Interventions

New Tools Same Focus Targeting Microvascular Disease in Type 2 Diabetes

New Ways to Learn Support and Grow in Diabetes Care With ADA Presidents Select Abstract Presentation

Newer Concepts in Management of Diabetes and Hypertriglyceridemia

Next-Generation Diabetic Foot Ulcer Care AI Cell Reprogramming and 3D Bioprinting With Roger Pecoraro Award Lecture

Not All Obesity Is the Same Identifying Rare Neuroendocrine Causes

Novel and Established Interventions to Improve Cardiovascular Outcomes

Novel Approaches to Glucose Control With ADA Presidents Select Abstract Presentation

Novel Insights into Basics Mechanisms and Therapeutic Interventions in Type 1 Diabetes

Novel Metabolic Drivers Underlying the Development of Obesity

Obesity Year in Review Major Advances and Discoveries

Old and New Tools to Understand Cardiovascular Risk With Edwin Bierman Award Lecture

Old Problems Bold Solutions Transforming Diabetes Screening with Innovative Solutions

Organellar Metabolite Carriers A New Frontier in Metabolic Research

Overcoming Technology Limitations

Pathways Regulating Glycemia Insulin Sensitization B-Cell Reserve and Glucose Sensing

Personalizing Diabetes Care Tailoring the Intervention to the Cardiovascular Risk

Perspectives from ADA Banting Medalists on Obesity Pathogenesis Current State and Future Directions

Perturb Observe What Pharmacologic Challenges Reveal about Human Metabolism

Pharmacogenomic Responses in Diabetes From Mice to Medications

Physiological Effects of Exercise

Precision Medicine in Diabetes Is It Time to Bring Genetics to the Clinic

Pregnancy Pregame Hot Topics in Preconception Management of Diabetes and Obesity

Preserving Lean Mass with GLP-1R Therapy Preclinical Obesity Studies

President Medicine Science Address and Banting Medal for Scientific Achievement Award Lecture

Preventing Diabetes-Related Complications

Preventing Type 1 Diabetes

Quality Improvement Initiatives at Scale What Have We Learned

Redesigning Diabetes Care What Is the Cost

Reprogram Replicate Replace Experimental Approaches to Durable B Cell Restoration

Rethinking RAAS Novel Strategies to Target a Classic Pathway in Diabetic Kidney Disease

Rising Minds AI Innovations in DiabetesNIDDK Early-Career Investigator Symposium

Session 1 Whats New with CGM Systems

Session 1 Whats New with Insulin Delivery Systems With ADA Presidents Select Abstract Presentation

Session 2 Whats New with CGM Systems

Session 2 Whats New with Insulin Delivery Systems

Severe Hypertriglyceridemia sHTG An Underrecognized Life-Threatening Disease

Sexual Dimorphism in Islet Responses in the Setting of Diabetes and Obesity

Short Talks from Abstracts Clinical Updates on PCSK9 Inhibition and Triglyceride-Related CVD

Signals In Signals Out The Human BrainBody Metabolic Circuit

Standards of Care in Overweight and Obesity 2026 Updates

Strengthening Community Engagement Principles in Your Research Best Practices and Lessons Learned from the National Center for Engagement in

The ADA and Centers for Diabetes Translation Research Symposium Driving Innovation in Diabetes Translation

The ADAs Standards of Care in Diabetes 2026 Updates

The AIDING Trial Automated Insulin Delivery in the HospitalResults and Implications for Inpatient Diabetes Care

The Benefits of GlucagonGLP-1 Receptor Dual Agonism Insights from the SYNCHRONIZE Phase 3 Studies of Survodutide

The Connected Continuum Reducing Clinician Burden Across Care Settings with EHR Integrated Diabetes Data

The Diabetic Foot Consortium An NIDDK Initiative to Transform Care of the Diabetic Foot Ulcer

The Glucagon Agonism Paradox Friend or Foe in the Fight against Hyperglycemia

The Molecular Nexus Inflammation ECM and Angiogenesis as Therapeutic Targets for Diabetic Foot Wounds

The Obesity Treatment Journey Evaluating Burden Discontinuation and Outcomes

The Omnipod Difference Patient-Centered Simplicity and Breakthrough Algorithm Performance

The Pancreas Revealed New Ways to Measure Form and Function

The Pancreatic Ecosystem How Exocrine Tissue Orchestrates Islet Biology

The Team The Team The Team What Works in Health Care Team Delivery

The Transformative Power of Continuous Glucose Monitoring

The twiist Grand Prix Precision for Every T1D Journey

The VESPER-1 OLE -2 and -3 Trials of Berobenatide MET-097 PF-08653944 an Ultra-Long Acting GLP-1 Receptor Agonist for Weight Management

To Pay or Not to Pay

Top Clinical Abstracts Kidney Complications in Diabetes With ADA Presidents Select Abstract Presentation

Top Research Abstracts Mechanisms of Diabetic Kidney Disease

Session 3 Whats New with CGM Systems

Translational Studies of Mechanisms Underlying Weight Gain and Long-Term Weight Loss in Obesity

Type 1 Diabetes Trends Complications and Survival

Undertreated and Underdiagnosed Bridging the Epidemics of Obesity and MASLD

Unexplored Pathways of Residual Risk in Diabetic Kidney Disease to Find Novel Cures

Unlocking the Potential of a Liver-Directed Treatment

Update of the ADA-EASD Consensus Report on the Management of Type 1 Diabetes in Adults

Updated Understanding of Reward Processing in Obesity in the Era of Incretin Agonists

Using Genetics to Elucidate Atypical Diabetes

Vapes and Vodka What Every Diabetes Professional Should Know about Addressing Adolescent and Young Adult Substance Use

Welcome to the 2026 ADA Scientific Sessions Keynote Address by Richard Woychik PhD Pathway to Stop Diabetes Symposium

What Works Outcomes of Behavioral Intervention Trials in Type 1 Type 2 and Gestational Diabetes

Why Would We Do Away with the Mouse Animal and Human Research Are Complementary